| Literature DB >> 36078557 |
Roberto De Masi1,2, Stefania Orlando2, Maria Carmela Costa3.
Abstract
Dementia-associated compulsive singing (DACS) is a neurotransmettitorial-based behavioral disturbance, characterized by an unabating melodic expression, occurring in patients that suffer from evolved dementia. Previously described only as a "punding" aspect of the dopamine dysregulation syndrome (DDS) in the Parkinson's disease (PD), compulsive singing has now been described, for the first time, in four non-PD patients effectively treated with Haloperidol or Quetiapine. Unlike the DDS-associated conditions, in our cases DACS is not pharmacologically induced, being that all patients were L-dopa-free. We detected a diffuse hyperintensity of the white matter and brain atrophy, with insular shrinkage as well as ventricular system and/or sub-arachnoid space enlargement in our DACS patients. Furthermore, similarly to the other behavioral symptoms of dementia, DACS also seems to be correlated to the degree of cognitive and functional impairment, rather than its subtype. In conclusion, DACS is a non-cognitive, unpublished clinical aspect of evolved dementia, which is interesting due to the involvement of the extra-nigral dopaminergic system, resulting in an unabating altered behavior, but also to the enrichment of our knowledge in the involutional diseases of the central nervous system and their physiopathological manifestations.Entities:
Keywords: L-dopa; compulsive singing; dementia; dopaminergic circuit; punding
Mesh:
Substances:
Year: 2022 PMID: 36078557 PMCID: PMC9517776 DOI: 10.3390/ijerph191710844
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Brain magnetic resonance imaging (MRI) short tau inversion recovery (STIR) sequences of (A) patient 1: note the enlargement of the ventricular system and subarachnoid spaces with mild hyperintensity of the occipital horns periventricular white matter; (B) patient 2: note the enlargement of subarachnoid spaces with diffuse deepening of the cortical sulci and a thinning of the cortical mantle, especially at the fronto-temporal lobes. The hyperintensity of the occipital horns periventricular white matter is also visible; (C) patient 3: note the slight diffuse shrinkage of the subcortical grey matter with several hyperintense lesions at semioval centers; (D) patient 4: note the subcortical chronic ischemic lesions with vascular encephalopathy and periventricular diffuse hyperintensity. Note the atrophy of insula as a common feature of these brains.
The clinical features of four unpublished cases affected by DACS.
| CASE 1 | CASE 2 | CASE 3 | CASE 4 | |
|---|---|---|---|---|
|
| Degenerative | Degenerative | Vascular | Vascular |
|
| Not applicable | Not applicable | 23.4 | Not applicable |
|
| Dysesecutive | Higher cortical functions involvement | Language and behavioral disturbances; | Alogic syndrome |
|
| 25 | 25 | 20 | 10 |
|
| Hypercholesterolemia, | Hypercholesterolemia, chronic ischemic heart disease, arterial | Arterial hypertension with labile therapeutic | Arterial hypertension, COPD, polyarthrosis |
|
| Haloperidol 0.5 mg | Haloperidol 0.5 mg three times daily; | 75 mg of Quetiapine daily and 0.5 mg of Haloperidol three times daily (poor efficacy in conjunction | 5 mg daily of |
|
| Ventricular and subarachnoid space enlargement, insular atrophy with greater left expression | Thinning of the cortical mantle, especially at the fronto-temporal lobes, | Slight diffuse shrinkage of the subcortical grey matter, hyperintense lesions | Chronic subcortical |
|
| Persistent chant without mood resonance | Persistent chant, poor | Persistent chant, poor | Persistent chant with |
|
| Incomplete | Primary school | Incomplete | Incomplete |
|
| Atorvastatine | Amlodipine 5 mg daily; Metformine 1000 mg twice daily; Glargine | Olmesartan 20 mg daily | Amlodipine 5 mg daily |
MMSE mini mental state examination; DACS dementia-associated compulsive singing; COPD chronic obstructive pulmonary disease; DMII type two diabetes mellitus; ASA acetylsalicylic acid; s.c. subcutaneous injection; IU international unit.